Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).
Date Range: 

 Krystal BiotechSangamo TherapeuticsTranslate BioC4 TherapeuticsScholar Rock
SymbolNASDAQ:KRYSNASDAQ:SGMONASDAQ:TBIONASDAQ:CCCCNASDAQ:SRRK
Price Information
Current Price$71.03$11.06$17.12$30.71$27.84
52 Week RangeBuyBuyBuyBuyBuy
MarketRank™
Overall Score1.51.31.61.41.5
Analysis Score3.53.34.33.53.5
Community Score2.52.51.83.12.3
Dividend Score0.00.00.00.00.0
Ownership Score1.70.81.70.00.8
Earnings & Valuation Score0.00.00.00.60.6
Analyst Ratings
Consensus RecommendationBuyBuyBuyBuyBuy
Consensus Price Target$101.00$20.20$25.70$44.50$61.60
% Upside from Price Target42.19% upside82.64% upside50.12% upside44.90% upside121.26% upside
Trade Information
Market Cap$1.58 billion$1.59 billion$1.29 billion$1.32 billion$953.88 million
Beta1.21.970.96N/A0.35
Average Volume155,2661,532,7701,232,804265,197294,371
Sales & Book Value
Annual RevenueN/A$102.43 million$7.80 millionN/A$20.49 million
Price / SalesN/A15.52165.08N/A46.55
CashflowN/AN/AN/AN/AN/A
Price / CashN/AN/AN/AN/AN/A
Book Value$11.72 per share$3.73 per share$2.56 per shareN/A$3.80 per share
Price / BookN/A2.976.69N/A7.33
Profitability
Net Income$-19,090,000.00$-95,190,000.00$-113,290,000.00N/A$-51,000,000.00
EPS($1.20)($0.85)($1.84)N/A($1.85)
Trailing P/E RatioN/AN/AN/A0.00N/A
Forward P/E RatioN/AN/AN/AN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net MarginsN/A-51.51%-70.38%N/A-365.84%
Return on Equity (ROE)-10.72%-16.32%-27.54%N/A-80.16%
Return on Assets (ROA)-10.40%-9.85%-12.82%N/A-41.33%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/AN/AN/AN/AN/A
Current Ratio39.96%5.67%5.73%5.22%3.63%
Quick Ratio39.96%5.67%5.73%5.22%3.63%
Ownership Information
Institutional Ownership Percentage73.05%57.69%92.90%N/A61.87%
Insider Ownership Percentage27.40%1.80%12.30%N/A24.60%
Miscellaneous
Employees5141312299119
Shares Outstanding22.20 million143.71 million75.21 million43.12 million34.26 million
Next Earnings Date5/3/2021 (Estimated)5/10/2021 (Estimated)5/6/2021 (Estimated)6/10/2021 (Estimated)5/6/2021 (Estimated)
OptionableNot OptionableOptionableNot OptionableNot OptionableNot Optionable
SourceHeadline
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Scholar Rock Holding Corporation - SRRKSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Scholar Rock Holding Corporation - SRRK
finance.yahoo.com - April 12 at 12:18 PM
Scholar Rock Presents Biomarker Strategy to Support the SRK-181 DRAGON Phase 1 Proof-of-Concept Trial at the American Association for Cancer Research Annual MeetingScholar Rock Presents Biomarker Strategy to Support the SRK-181 DRAGON Phase 1 Proof-of-Concept Trial at the American Association for Cancer Research Annual Meeting
finance.yahoo.com - April 10 at 12:49 PM
Scholar Rock (NASDAQ:SRRK) Trading Down 4.4%Scholar Rock (NASDAQ:SRRK) Trading Down 4.4%
americanbankingnews.com - April 8 at 2:14 PM
Scholar Rock posts positive phase II data in spinal muscular atrophyScholar Rock posts positive phase II data in spinal muscular atrophy
bioworld.com - April 6 at 10:23 PM
Mid-Day Market Update: Crude Oil Rises Over 2%; Scholar Rock Shares PlungeMid-Day Market Update: Crude Oil Rises Over 2%; Scholar Rock Shares Plunge
markets.businessinsider.com - April 6 at 5:23 PM
Mid-day market update: Crude Oil rises over 2%; Scholar Rock (SRRK Stock) shares plungeMid-day market update: Crude Oil rises over 2%; Scholar Rock (SRRK Stock) shares plunge
fxstreet.com - April 6 at 5:23 PM
Scholar Rock Holding is Now Oversold (SRRK)Scholar Rock Holding is Now Oversold (SRRK)
nasdaq.com - April 6 at 5:23 PM
Why Scholar Rock Shares Dropped Despite Positive Apitegromab Data In Spinal Muscular AtrophyWhy Scholar Rock Shares Dropped Despite Positive Apitegromab Data In Spinal Muscular Atrophy
finance.yahoo.com - April 6 at 5:23 PM
Scholar Rock eyes phase 3 after confirming effects of SMA drugScholar Rock eyes phase 3 after confirming effects of SMA drug
fiercebiotech.com - April 6 at 12:23 PM
Scholar Rock Announces Positive 12-Month Top-Line Results From the TOPAZ Phase 2 Clinical Trial Evaluating Apitegromab in Patients With Type 2 and TypScholar Rock Announces Positive 12-Month Top-Line Results From the TOPAZ Phase 2 Clinical Trial Evaluating Apitegromab in Patients With Type 2 and Typ
us.acrofan.com - April 6 at 12:23 PM
Scholar Rock Reports Apitegromab Data In Spinal Muscular AtrophyScholar Rock Reports Apitegromab Data In Spinal Muscular Atrophy
finance.yahoo.com - April 6 at 12:23 PM
Scholar Rock (NASDAQ:SRRK) Shares Gap Down to $45.13Scholar Rock (NASDAQ:SRRK) Shares Gap Down to $45.13
americanbankingnews.com - April 6 at 11:40 AM
Scholar Rock Announces Positive 12-Month Top-Line Results From the TOPAZ Phase 2 Clinical Trial Evaluating Apitegromab in Patients With Type 2 and Type 3 Spinal Muscular Atrophy (SMA)Scholar Rock Announces Positive 12-Month Top-Line Results From the TOPAZ Phase 2 Clinical Trial Evaluating Apitegromab in Patients With Type 2 and Type 3 Spinal Muscular Atrophy (SMA)
finance.yahoo.com - April 6 at 7:23 AM
Scholar Rock (NASDAQ:SRRK) Trading Down 4.8%Scholar Rock (NASDAQ:SRRK) Trading Down 4.8%
americanbankingnews.com - April 1 at 3:44 PM
Scholar Rock Announces Publication of Preclinical Pharmacology, Pharmacokinetics, and Safety Profile of SRK-181 in the International Journal of ToxicoScholar Rock Announces Publication of Preclinical Pharmacology, Pharmacokinetics, and Safety Profile of SRK-181 in the International Journal of Toxico
us.acrofan.com - March 22 at 7:06 PM
Scholar Rock Announces Publication of Preclinical Pharmacology, Pharmacokinetics, and Safety Profile of SRK-181 in the International Journal of ToxicologyScholar Rock Announces Publication of Preclinical Pharmacology, Pharmacokinetics, and Safety Profile of SRK-181 in the International Journal of Toxicology
finance.yahoo.com - March 22 at 7:06 PM
Scholar Rock Holding Co. (NASDAQ:SRRK) Given Average Rating of "Buy" by BrokeragesScholar Rock Holding Co. (NASDAQ:SRRK) Given Average Rating of "Buy" by Brokerages
americanbankingnews.com - March 21 at 2:40 PM
Zacks: Brokerages Expect Scholar Rock Holding Co. (NASDAQ:SRRK) to Announce -$0.66 Earnings Per ShareZacks: Brokerages Expect Scholar Rock Holding Co. (NASDAQ:SRRK) to Announce -$0.66 Earnings Per Share
americanbankingnews.com - March 20 at 12:10 PM
Scholar Rock (NASDAQ:SRRK) Shares Gap Up to $60.72Scholar Rock (NASDAQ:SRRK) Shares Gap Up to $60.72
americanbankingnews.com - March 19 at 3:48 PM
Scholar Rock Announces the Addition of Joshua Reed to Its Board of DirectorsScholar Rock Announces the Addition of Joshua Reed to Its Board of Directors
finance.yahoo.com - March 19 at 9:51 AM
Scholar Rock Announces Issuance of U.S. Patent Protecting Add-On or Combination Therapy with a Myostatin Inhibitor for the Treatment of Spinal MusculaScholar Rock Announces Issuance of U.S. Patent Protecting Add-On or Combination Therapy with a Myostatin Inhibitor for the Treatment of Spinal Muscula
us.acrofan.com - March 17 at 7:01 PM
Scholar Rock Announces Issuance of U.S. Patent Protecting Add-On or Combination Therapy with a Myostatin Inhibitor for the Treatment of Spinal Muscular AtrophyScholar Rock Announces Issuance of U.S. Patent Protecting Add-On or Combination Therapy with a Myostatin Inhibitor for the Treatment of Spinal Muscular Atrophy
finance.yahoo.com - March 17 at 7:01 PM
Scholar Rock Presents TOPAZ Interim Analysis Data for Apitegromab in Spinal Muscular Atrophy at the 2021 Muscular Dystrophy Association (MDA) VirtualScholar Rock Presents TOPAZ Interim Analysis Data for Apitegromab in Spinal Muscular Atrophy at the 2021 Muscular Dystrophy Association (MDA) Virtual
us.acrofan.com - March 15 at 9:33 AM
Scholar Rock Presents TOPAZ Interim Analysis Data for Apitegromab in Spinal Muscular Atrophy at the 2021 Muscular Dystrophy Association (MDA) Virtual Clinical & Scientific ConferenceScholar Rock Presents TOPAZ Interim Analysis Data for Apitegromab in Spinal Muscular Atrophy at the 2021 Muscular Dystrophy Association (MDA) Virtual Clinical & Scientific Conference
finance.yahoo.com - March 15 at 9:33 AM
Scholar Rock Holding Corporation (SRRK) Reports Q4 Loss, Misses Revenue EstimatesScholar Rock Holding Corporation (SRRK) Reports Q4 Loss, Misses Revenue Estimates
finance.yahoo.com - March 9 at 10:34 PM
DateCompanyBrokerageAction
3/8/2021Krystal BiotechHC WainwrightBoost Price Target
2/9/2021Krystal BiotechJonestradingInitiated Coverage
11/11/2020Krystal BiotechB. RileyReiterated Rating
8/25/2020Krystal BiotechChardan CapitalReiterated Rating
6/4/2020Krystal BiotechEvercore ISIInitiated Coverage
5/4/2020Krystal BiotechWilliam BlairReiterated Rating
11/5/2019Krystal BiotechCowenReiterated Rating
9/26/2019Krystal BiotechGuggenheimSet Price Target
9/24/2019Krystal BiotechThe Goldman Sachs GroupInitiated Coverage
3/3/2021Sangamo TherapeuticsWells Fargo & CompanyLower Price Target
1/5/2021Sangamo TherapeuticsStifel NicolausInitiated Coverage
9/8/2020Sangamo TherapeuticsBank of AmericaInitiated Coverage
7/7/2020Sangamo TherapeuticsSunTrust BanksInitiated Coverage
6/19/2020Sangamo TherapeuticsWedbushReiterated Rating
11/14/2018Sangamo TherapeuticsJPMorgan Chase & Co.Downgrade
3/29/2021Translate BioSVB LeerinkReiterated Rating
3/24/2021Translate BioTruist SecuritiesReiterated Rating
3/24/2021Translate BioRoth CapitalLower Price Target
8/19/2020Translate BioCitigroupLower Price Target
6/23/2020Translate BioJefferies Financial GroupBoost Price Target
3/31/2021C4 TherapeuticsBMO Capital MarketsInitiated Coverage
10/28/2020C4 TherapeuticsUBS GroupInitiated Coverage
1/11/2021Scholar RockCredit Suisse GroupInitiated Coverage
10/27/2020Scholar RockRobert W. BairdReiterated Rating
(Data available from 4/12/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.